

Investor Presentation

January 2025

Forward Looking Statements

This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any “phase” of clinical trials. We also cannot be sure of the clinical outcome for efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.

We are Dedicated to Pushing the Boundaries of Scientific Discovery With Novel Oral Small Molecules Tailored to Potentially Offer Hope and Relief.



Worldwide Alzheimer's - Dementia Cases Projected to Grow to Over 130M by 2050

We believe we are positioned to capitalize on a significant and growing market opportunity to treat CNS diseases

>$20T

Cumulative costs of Alzheimer's and dementia care from 2015 to 2050

1 in 3

Medicare dollars will be spent on people living with Alzheimer's and other dementias in 2050

>11M

The number of Americans providing unpaid care for people with Alzheimer's or other dementias

Targeting these markets using a differentiated and transformative precision platform

PEOPLE LIVING WITH **DEMENTIA** AROUND THE WORLD



Source: World Alzheimer's Report

Anavex Investment Highlights



Wide international patent protection for product candidates

- Regulatory submission stage CNS Precision Medicine platform Company with novel central nervous system mechanism
- Meet with regulatory authorities to discuss full Phase 2b/3 Alzheimer's data with aim to bring Alzheimer's therapy to patients in Europe, Asia-Pacific, and the U.S., including potential approval pathway based on available efficacy results of surrogate biomarkers
- Estimated that operations and clinical programs are funded for 4 years. No debt
- Oral drug Blarcamesine demonstrated superior clinical safety and efficacy compared to mAb Leqembi (Lecanemab) and mAb Kisunla (Donanemab) and slows neurodegeneration in Early Alzheimer's Disease[1,2,3]

Blarcamesine: Oral once daily convenient scalable treatment

1. *https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimer-sdisease*
2. *van Dyck CH et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023; 388(1): 9–21*
3. *Sims JR et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6): 512–27*

Foundation for More Cost Effective & Safer Treatments for CNS Conditions

Oral Solid
ANAVEX®2-73 (blarcamesine)

- Alzheimer's Disease
- Parkinson's Disease
- Parkinson's Disease Dementia

Oral Liquid
ANAVEX®2-73 (blarcamesine)

- Rett Syndrome
- Fragile X Syndrome
- Infantile Spasms
- Angelman Syndrome

Oral Solid
ANAVEX®3-71 (AF710B)

- Schizophrenia
- Frontotemporal Dementia (FTD)
- Alzheimer's Disease



Orally-administered candidates offer significant potential for clinical benefit relative to costly and logistically challenging biologic mAb-based drugs, which also often present additional safety challenges

~60%
of established small-molecule drug products available commercially are administered orally[1]

~90%
of the global market share of all pharmaceutical formulations for humans are oral[1]

~84%
of the best-selling pharmaceutical products are orally administered[1]

1. *Prasad V., De Jesús K., Mailankody S. (2017). The high price of anticancer drugs: origins, implications, barriers, solutions. Nat. Rev. Clin. Oncol. 14 (6), 381. 10.1038/nrclinonc.2017.31*

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities

Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration

Multiple clinical milestones and promising pipeline with potential progress towards commercialization

Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease

We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation

Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Anavex Precision Platform Enables a Novel Approach

Targeting CNS conditions with precision and **restoring neuronal homeostasis** via **SIGMAR1 activation**

Proprietary SIGMACEPTOR™ Discovery Platform produces small molecule therapeutic candidates for targeting the SIGMAR1 receptor

SIGMAR1 target binding affinity is so specific that even when patients carry a variant receptor, still powerful effects observed. All patients regardless of genotype stand to benefit

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD

Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. *Cells*. 2019;8(3):211.
Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. *Autophagy*. 2019;15(9):1539-1557.
Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. *Nature Neuroscience*. 2022;25(6):688-701.

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD

Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. *Cells*. 2019;8(3):211.
Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. *Autophagy*. 2019;15(9):1539-1557.
Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. *Nature Neuroscience*. 2022;25(6):688-701.

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD



Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. *Cells*. 2019;8(3):211.
Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. *Autophagy*. 2019;15(9):1539-1557.
Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. *Nature Neuroscience*. 2022;25(6):688-701.

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD

Blarcamesine (oral drug)

Aging ⊣ **Survival of Brain Cells** ⊣ **Neurotoxicity (β-amyloid, Tau)**

monoclonal Antibodies (IV infusion) → **Microglial phagocytosis** → **Downstream removal of β-amyloid plaques** ↑

Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. *Cells*. 2019;8(3):211.
Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. *Autophagy*. 2019;15(9):1539-1557.
Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. *Nature Neuroscience*. 2022;25(6):688-701.

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD

Blarcamesine (oral drug)

SIGMAR1 activation → **Autophagy** → **Upstream neuroprotection (Remove, Repair, Regenerate, Resilience)**

Aging ⊣ **Survival of Brain Cells** ⊣ **Neurotoxicity (β-amyloid, Tau)**

monoclonal Antibodies (IV infusion) → **Microglial phagocytosis** → **Downstream removal of β-amyloid plaques**

Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. *Cells*. 2019;8(3):211.
Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. *Autophagy*. 2019;15(9):1539-1557.
Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. *Nature Neuroscience*. 2022;25(6):688-701.

Precision Platform Shows Promise for Superior Care

We believe Anavex is positioned to target significant unmet medical needs across multiple CNS conditions

Achieved

SIGMAR1 activation established as a new platform class

- ☑ **ANAVEX®2-73 (blarcamesine)** Clinical study results in broad CNS indications confirm SIGMAR1 technology
- ☑ **Rett syndrome:** Top-line data EXCELLENCE Phase 2/3 ANAVEX®2-73 pediatric clinical trial
- ☑ **ANAVEX®3-71:** Publication Phase 1 clinical trial
- ☑ **Parkinson's disease dementia:** Data of 48-week OLE Phase 2 study
- ☑ **Alzheimer's disease:** Top-line data ANAVEX®2-73-AD-004: Potentially pivotal Phase 2b/3 clinical trial
- ☑ **Schizophrenia:** Initiation of ANAVEX®3-71 Phase 2 clinical trial

Near Term

SIGMAR1 technology to succeed traditional modalities

- ☑ **Alzheimer's disease:** Full regulatory submission of blarcamesine in Europe (EMA)
- ☑ **Alzheimer's disease:** Data from the blarcamesine Phase 2b/3 ANAVEX®2-73-AD-004 trial to be published in an upcoming peer-reviewed journal expected Q1 2025
- ☐ **Alzheimer's disease:** Analysis of RNA sequencing (RNA-seq) of the Phase 2b/3 data expected 2025
- ☑ **Alzheimer's disease:** ATTENTION-AD OLE 96/144-week Top-line trial data January 2025
- ☐ **Schizophrenia:** Top-line data of ANAVEX®3-71 Phase 2 clinical trial expected 2025
- ☐ **Parkinson's disease:** Initiation of ANAVEX®2-73 imaging-focused trial or Phase 2b/3 >6 months trial
- ☐ **Fragile X:** Initiation of ANAVEX®2-73 Phase 2/3 clinical trial
- ☐ **New Rare disease:** Initiation of ANAVEX®2-73 Phase 2/3 clinical trial
- ☐ **Publications:** Continued clinical publications involving ANAVEX®2-73 and ANAVEX®3-71

Long Term

SIGMAR1 to potentially open up new opportunities beyond the horizon

- Expanded CNS indications
- Regenerative medicine[1]
- Disease prevention[2]

1. 1 K. Ruscher, T. Wieloch, The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration, Journal of Pharmacological Sciences, Volume 127, Issue 1, 2015, Pages 30-35, ISSN 1347-8613, https://doi.org/10.1016/j.jphs.2014.11.011.
2. L. Nguyen et al., Role of sigma-1 receptors in neurodegenerative diseases, Journal of Pharmacological Sciences, Volume 127, Issue 1, 2015, Pages 17-29, ISSN 1347-8613, https://doi.org/10.1016/j.jphs.2014.12.005.

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities

Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration

Multiple clinical milestones and promising pipeline with potential progress towards commercialization

Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease

We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation

Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Multiple Clinical Milestones and Promising Pipeline with Potential Progress towards Commercialization



** Orphan Drug Designation by FDA*

Treating Alzheimer's Disease (AD)

Progressive, neurological disease and the most common cause of dementia in humans[1]

- Progressive development; slowly destroys memory and thinking skills in people
- **Impacts families** and nearly **every aspect** of a person's life as it progresses: short-term memory loss and confusion, difficulty learning new things, delusions and disorientation, inability to recognize common things in people
- Current annual cost of dementia is estimated at $1T, a figure set to double by 2030

~35M
people worldwide living with AD[2]

~6.9M
people in the U.S. living with AD[2]

CANDIDATE	STAGE 1	STAGE 2	STAGE 3	STAGE OLE
ANAVEX®2-73 (blarcamesine)	✓ ANAVEX®2-73-001	✓ AD ANAVEX®2-73-002/3	✓ AD ANAVEX®2-73-004	✓ (Ongoing EMA)
ANAVEX®3-71	✓ ANAVEX®3-71-001	✓ (Planned Trial)		

1. Source: www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia
2. Sources available on slide 28 of this presentation.

Treating Parkinson's Disease (PD) & Parkinson's Disease Dementia (PDD)

Motor disorder in which patients suffer from tremors in their extremities and head, stiff limbs and inability to relax muscles during episodes

- Up to 80% of those with Parkinson's disease (PD) eventually experience Parkinson's disease dementia[1]
- Progressive development; can cause numerous cognitive and behavioral deficits
- Parkinson's disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2% of those over the age of 65

	CANDIDATE	STAGE 1	STAGE 2	STAGE 3
PARKINSON'S DISEASE	ANAVEX®2-73 (blarcamesine)	✓ ANAVEX®2-73-001	✓ (Planned Trial)	✓ (Planned Trial)
PARKINSON'S DISEASE DEMENTIA	ANAVEX®2-73 (blarcamesine)	✓ ANAVEX®2-73-001	✓ PDD ANAVEX®2-73-PDD-001	✓ (Planned Trial)



>1%
of the world population has PD[2]

>1.5M
Americans affected by PD today[2]

1. *Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. PMID: 28257128; PMCID: PMC5643027;*
2. *www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia*

Treating Rett Syndrome

Neuro-developmental disease in girls with both movement impairment and cognitive impairment[1]

- Second most common cause of severe intellectual disability in females
- Cognitive and motor delays begin to manifest along with slower head growth following relatively normal infancy (~1.5 to 3 years of age, loss of spoken language, and hand skills begin to develop)
- Associated with four key symptoms: **loss of expressive language, loss of fine motor skills, impaired ability to walk and repetitive hand movement**

CANDIDATE	STAGE 1	STAGE 2	STAGE 3
ANAVEX®2-73 - Pediatrics (blarcamesine)	✓ ANAVEX®2-73-001	✓ EXCELLENCE ANAVEX®2-73-RS-003	✓ (Planned Trial)
ANAVEX®2-73 - Adults (blarcamesine)	✓ ANAVEX®2-73-001	✓ U.S. ANAVEX®2-73-RS-001	
ANAVEX®2-73 - Adults (blarcamesine)	✓ ANAVEX®2-73-001		✓ AVATAR ANAVEX®2-73-RS-002

~350,000
patients diagnosed with Rett Syndrome worldwide[1]

~11,000
patients diagnosed with Rett Syndrome in the U.S.[2]

1. *Source: https://www.rettsyndrome.org/about-rett-syndrome.*
2. *Sources available on slide 28 of this presentation.*

Real World Evidence (RWE): Patients with Rett Syndrome Positive Feedback with Blarcamesine

Voice of the Patients: Real World Evidence (RWE)

- Brigitte: "*We did get a surprise once with her mobility. We heard a noise from our family room, and next we looked, and Madeline had climbed twelve steps upstairs to her bedroom by herself.*"
- Jayne: "*Within a week of starting the Anavex open label extension, she only had one seizure and then she went three months without a seizure.*"
- See related link for more video comments from parents at RSAA/parent stories.
- >91% of patients completing the EXCELLENCE trial continued into a 48-week open-label extension study (OLE)
- To date, of the pediatric patients who completed the OLE, 93% have joined the Compassionate Use Program
- Compassionate Use level for adult patients from AVATAR trial after 48-week OLE is >96%
- As of today, some patients with Rett syndrome have been **on blarcamesine-treatment for >4 years**, combined OLE and Compassionate Use Program

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities

Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration

Multiple clinical milestones and promising pipeline with potential progress towards commercialization

Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease

We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation

Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

AD-004 Phase 2b/3 Early Alzheimer's Disease Trial

Global, multicenter, randomized, double-blind, placebo-controlled, parallel group, 48-week trial evaluating Blarcamesine (ANAVEX®2-73) once-daily oral capsules



Key eligibility criteria:

- Met the NIA-AA 2011 criteria for diagnosis of early-stage mild dementia or MCI due to AD
- Aged 60 to 85 years
- MMSE score 20-28
- Confirmation of AD via amyloid or FDG PET, CT or MRI scan, or CSF (amyloid or tau)[1]

Co-primary endpoints*

- ADAS-Cog13
- ADCS-ADL

Key secondary endpoint

- CDR-SB

Other endpoints

- Structural and functional MRI
- Biomarkers: $A\beta_{42}/A\beta_{40}$, p-tau (181), p-tau (231), Nf-L
- CGI-I

ATTENTION-AD study

*With the March 2024 FDA Guidance for Early AD, a sole cognitive measure can serve as the primary endpoint for early AD trials

1. AD status supported by the elevated baseline levels of plasma p-Tau(181) and p-Tau(231)
2. Titration occurred from days 1-21

AD, Alzheimer's disease; ADAS-Cog13, a 13-item cognitive subscale of the Alzheimer's Disease Assessment Scale; ADCS-ADL, AD Cooperative Study-Activities of Daily Living Scale; CDR-SB, Clinical Dementia Rating-Sum of Boxes; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NIA-AA, National Institute on Aging- Alzheimer's Association. Nf-L, neurofilament light chain.

Alzheimer's Disease Pathology Manifested in Brain Volume Loss (Atrophy) of the Brain

Brain volume loss (atrophy) in Alzheimer's disease (AD)[1]



1. Exemplified by defying dememtia lancaster.ac.uk/defyingdementia

Reduced Atrophy of the Brain in Blarcamesine-treated Patients Compared to Placebo

Significant slowing of atrophy in broad brain regions after 48 weeks of treatment[1]



1. https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimer-sdisease

ATTENTION-AD AD-004 OLE Phase IIb/III Early Alzheimer's Disease

Global, multicenter, randomized, Open-Label-Extension (OLE), 96/144-week trial evaluating Blarcamesine (ANAVEX®2-73) once-daily oral capsules, following placebo-controlled 48-week trial[1]



1. The preceding double-blind study (ANAVEX®2-73-AD-004) had started in Australia before the other regions (Europe and North America). This did not allow time for the other regions to also participate in the additional OLE extension beyond the initial 96 Weeks OLE period, which was extended to 144 Weeks upon investigators request in Australia.

2. The scheduled visits were [OLE Week 0 = Combined Week 48], [OLE Week 48 = Combined Week 96], [OLE Week 96 = Combined Week 144] and [OLE Week 144 = Combined Week 192]; Combined = OLE (open-label-extension) + DB (double-blind) studies.

anavex LIFE SCIENCES Corp.

Delayed-Start Analysis ATTENTION-AD and AD-004 Trial

Top-line data:

Key safety findings

- No new safety findings observed with blarcamesine over four (4) years
- There were no deaths related to the study drug

Key efficacy findings

- Treatment LS mean difference continued to increase up to Week 192:
- ADAS-Cog13 difference: -3.83 *P* = 0.0165
- ADCS-ADL difference: +4.30 *P* = 0.0206)

Summary

Suggests earlier blarcamesine treatment initiation may have continued long-term beneficial therapeutic effect

ADAS-Cog13 difference larger than 2 points are considered clinically meaningful improvements*

* Muir RT, Hill MD, Black SE, Smith EE. Minimal clinically important difference in Alzheimer's disease: Rapid review. Alzheimers Dement. 2024;20(5):3352-3363. doi:10.1002/alz.13770

Anavex's Blarcamesine Advantage:

- ✓Oral administration
- ✓Novel target that impacts neurodegeneration
- ✓Promising clinical results

The Journal of Prevention of Alzheimer's Disease 12 (2025) 100016

Contents lists available at ScienceDirect

The Journal of Prevention of Alzheimer's Disease

journal homepage: www.elsevier.com/locate/tjpad

Original Article

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Stephen Macfarlane[a], Timo Grimmer[b], Ken Teo[a], Terence J O'Brien[c], Michael Woodward[d], Jennifer Grunfeld[e], Alastair Mander[f], Amy Brodtmann[g], Bruce J. Brew[h], Philip Morris[i], Cathy Short[j], Susan Kurrle[k], Rosalyn Lai[l], Sneha Bharadwaj[m], Peter Drysdale[n], Jonathan Sturm[o], Simon J.G. Lewis[p], David Barton[q], Chris Kalafatis[r], Saif Sharif[s], Richard Perry[t], Nicholas Mannering[u], J.Emer MacSweeney[v], Stephen Pearson[w], Craig Evans[x], Vivek Krishna[y], Alex Thompson[z], Malathy Munisamy[aa], Neel Bhatt[bb], Aliya Asher[cc], Sandra Connell[dd], Jennifer Lynch[ee], Sterre Malou Rutgers[ff], Paul LJ Dautzenberg[gg], Niels Prins[hh], Patrick Oschmann[ii], Lutz Frölich[jj], Pawel Tacik[kk], Oliver Peters[ll], Jens Wiltfang[mm], Alexandre Henri-Bhargava[nn], Eric Smith[oo], Stephen Pasternak[pp], Andrew Frank[qq], Howard Chertkow[rr], Jennifer Ingram[ss], Ging-Yuek Robin Hsiung[tt], Rodney Brittain[uu], Carmela Tartaglia[vv], Sharon Cohen[ww], Luca M Villa[xx], Elizabeth Gordon[xx], Thomas Jubault[yy], Nicolas Guizard[yy], Amanda Tucker[zz], Walter E Kaufmann[zz], Kun Jin[zz],

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities

Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration

Multiple clinical milestones and promising pipeline with potential progress towards commercialization

Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease

We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation

Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Exploring Commercial Activities

Examining innovative strategies to effectively engage patients, providers and payers



Source: https://nam.edu/assessing-meaningful-community-engagement-a-conceptual-model-to-advance-health-equity-through-transformed-systems-for-health/

High demand from Alzheimer's disease patients and families for easy access and scalable treatment options

Intended to reduce the need for complex procedures for the treatment of people with Alzheimer's disease

Blarcamesine **orally once daily** versus challenges of biologic mAb-based intravenous drug

Addressable CNS Diseases Globally with Therapeutic Disruption Potential

U.S. AND GLOBAL PATIENT NUMBERS

INDICATION	USA	EUROPE	ASIA	GLOBAL
Alzheimer's Disease (AD)[1,2]	~6,900,000	~7,000,000	~23,000,000	~35,000,000
Parkinson's Disease (PD)[3,4]	~1,000,000	~1,400,000	~3,000,000	~10,000,000
Schizophrenia[5,6*]	~1,600,000	~3,000,000	~9,000,000	~24,000,000
Frontotemporal Dementia (FTD)[7]	~60,000	~65,000	~500,000	~800,000
Rett Syndrome (RTT)[8*]	~11,000	~13,000	~37,000	~350,000
Fragile X Syndrome (FXS)[9,10*]	~62,500	~150,000	~900,000	~1,400,000

1. Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures
2. *Dementia in the Asia Pacific Region. Alzheimer's Disease International 2014; 10*
3. *Marras C et al 2018. npj Parkinson's Disease volume 4, Article number: 21*
4. *GBD 2016 Parkinson's Disease Collaborators. The Lancet 2018 Volume 17, Issue 11, P3939-953*
5. *National Alliance on Mental Illness, 2019; Schizophrenia. World Health Organization. Accessed January 2024. https://www.who.int/news-room/fact-sheets/detail/schizophrenia*
6. *Fasseh et al., 2018. Eur J Public Health. 2018 Dec 1;28(6):1043-1049*
7. *Knopman & Roberts 2011. J Mol Neurosci 2011;45(3):330-335*
8. *Rettsyndrome.org, 2016*
9. *National Fragile X Foundation, 2022*
10. *Hunter et al., 2014. Am J Med Genet A. 2014 Jul;164A(7):1648-5*

** Patient estimates derived from the published prevalence estimate range for the regional population*

Worldwide Commercial Rights to Capitalize on Valuable Pipeline and Global Opportunity

Aiming to bring lead therapies to patients in Europe, Asia-Pacific, and the U.S. following regulatory discussion



Wide international patent protection to 2030-2039 for product candidates

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities

Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration

Multiple clinical milestones and promising pipeline with potential progress towards commercialization

Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease

We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation

Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Anavex's Strong Financial Profile Supports Operations and Clinical Programs are Funded for 4 Years

Strong balance sheet supported by non-dilutive funding sources

$132.2M
Cash and cash equivalents[1]

~84M
Shares outstanding[1]

Non-dilutive funding sources

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

International Rett Syndrome Foundation
www.rettsyndrome.org

Disciplined approach to operational expenditures

30.8M
Fiscal year 2024 cash utilization

Sufficient cash runway

4
Est. Years of Runway

Sustainable cash runway due to disciplined operations and non-dilutive cash sources

1. *As of Sept 30, 2024*

Values-Driven Team with Track Record and Expertise Capable of Advancing Anavex's Cutting-Edge Precision Platform

Christopher U. Missling, PhD
President & CEO

20+ years of experience in the healthcare industry within large pharmaceutical companies, the biotech industry and investment banking

Juan Carlos Lopez-Talavera, MD, PhD
SVP Head of Research and Development

25+ years of key leadership in managing registrational clinical trials and led and contributed to the development and approvals of several treatments in USA, Europe and Asia

Terrie Kellmeyer, PhD
SVP of Clinical Development

28+ years of experience in executive leadership positions in clinical development, clinical operations, regulatory affairs, and medical affairs

Jeffrey Edwards, PhD
VP of Clinical Pharmacology

18+ years of drug development including clinical pharmacology and clinical science

Kun Jin, PhD
VP Head of Biostatistics

27+ years of experience with US Food and Drug Administration (FDA)

Daniel Klamer, PhD
VP of Business Development & Scientific Strategy

15+ years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the USA

Purpose-Built Scientific Advisory Board

Diverse skillset tailored to Anavex's portfolio

- CNS Drug development
- Trial design and analysis
- Academic and research thought leadership
- Clinical expertise in treating CNS diseases

Andrew Cole, MD
Harvard Medical School

Corinne Lasmezas, PhD
Scripps Research

Dag Aarsland, MD, PhD
King's College London

Daniel Weintraub, MD
Perelman School of Medicine, University of Pennsylvania

Jacqueline French, MD
NYU

Jeffrey Cummings, MD
Cleveland Clinic

Norman Relkin, MD, PhD
Weill Cornell Medicine

Ottavio Arancio, MD, PhD
Columbia University Medical Center

Paul Aisen, MD
USC University of Southern California

Tangui Maurice, PhD
Université de Montpellier

Timo Grimmer, MD
Technische Universität München

Marwan Sabbagh, MD
Barrow Neurological Institute

Anavex's Advantage is Precision Medicine Platform Scalability

Equitable and Accessible for Diverse Populations, and Maintaining Sustainability within Global Healthcare Systems



Contact Us

Corporate Office

Anavex Life Sciences Corp.
630 5th Avenue, 20th floor
New York, NY 10111

1-844-689-3939

Shareholder & Media Relations

ir@anavex.com
www.anavex.com

NASDAQ: AVXL